These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 14556604)
21. UNITAID can address HCV/HIV co-infection. von Schoen-Angerer T; Cohn J; Swan T; Piot P Lancet; 2013 Feb; 381(9867):628. PubMed ID: 23439101 [No Abstract] [Full Text] [Related]
22. Anemia during treatment of hepatitis C in HIV-infected patients. Lo Re V; Kostman JR AIDS Read; 2004 Oct; 14(10):555-7, 562, 565-71. PubMed ID: 15510392 [TBL] [Abstract][Full Text] [Related]
23. [Interferon therapy for hepatitis B and C]. Iino S Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():559-63. PubMed ID: 17455681 [No Abstract] [Full Text] [Related]
24. Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy. Fuster D; Huertas JA; Gómez G; Solà R; González García J; Vilaró J; Pedrol E; Force L; Tor J; Sirera G; Videla S; Planas R; Clotet B; Tural C; Antivir Ther; 2005; 10(7):841-7. PubMed ID: 16312180 [TBL] [Abstract][Full Text] [Related]
25. Antiviral therapy for hepatitis C virus recurrence after liver transplantation in HIV-infected patients: outcome in the Bonn cohort. Wojcik K; Vogel M; Voigt E; Speidel N; Kalff JC; Goldmann G; Oldenburg J; Sauerbruch T; Rockstroh JK; Spengler U AIDS; 2007 Jun; 21(10):1363-5. PubMed ID: 17545715 [TBL] [Abstract][Full Text] [Related]
26. [Epidemiological, clinical and therapeutical aspects of HIV/HCV coinfection in a series of HIV seropositive Umbrian patients]. Francisci D; Valente M; Di Candilo F; Sfara C; Conte ME; Canovari B; Baldelli F; Stagni G Recenti Prog Med; 2004 Nov; 95(11):521-4. PubMed ID: 15598089 [TBL] [Abstract][Full Text] [Related]
27. Early antiviral treatment of hepatitis C virus recurrence after liver transplantation in HIV-infected patients. Castells L; Esteban JI; Bilbao I; Vargas V; Allende H; Ribera E; Piron M; Sauleda S; Len O; Pahissa A; Esteban R; Guardia J; Margarit C Antivir Ther; 2006; 11(8):1061-70. PubMed ID: 17302376 [TBL] [Abstract][Full Text] [Related]
28. New paradigms in the management of hepatitis C virus co-infections. Sherman KE Nat Clin Pract Gastroenterol Hepatol; 2007 Jan; 4 Suppl 1():S10-6. PubMed ID: 17235280 [TBL] [Abstract][Full Text] [Related]
29. Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus. Aguilar Marucco D; Veronese L; de Requena DG; Bonora S; Calcagno A; Cavecchia I; Sinicco A; De Rosa FG; Cariti G; Di Perri G J Antimicrob Chemother; 2007 Mar; 59(3):565-8. PubMed ID: 17213263 [TBL] [Abstract][Full Text] [Related]
30. Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis. Shire NJ; Welge JA; Sherman KE J Viral Hepat; 2007 Apr; 14(4):239-48. PubMed ID: 17381715 [TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection. Hornberger J; Torriani FJ; Dieterich DT; Bräu N; Sulkowski MS; Torres MR; Green J; Patel K J Clin Virol; 2006 Aug; 36(4):283-91. PubMed ID: 16765638 [TBL] [Abstract][Full Text] [Related]
32. PegIFN/ribavirin during acute HCV coinfection. Bernard EJ IAPAC Mon; 2004 Jul; 10(7):260-1. PubMed ID: 15624247 [No Abstract] [Full Text] [Related]
33. Management of hepatitis C virus coinfection in HIV-infected persons. O'Leary JG; Chung RT AIDS Read; 2006 Jun; 16(6):313-6, 318-20. PubMed ID: 16795921 [TBL] [Abstract][Full Text] [Related]
34. Fulminant autoimmune hepatitis after successful interferon treatment in an HIV-HCV co-infected patient. Coriat R; Podevin P Int J STD AIDS; 2008 Mar; 19(3):208-10. PubMed ID: 18397566 [TBL] [Abstract][Full Text] [Related]
35. Cryptosporidiosis in a patient on PEG-interferon and ribavirin for recurrent hepatitis C after living donor liver transplantation. Manz M; Steuerwald M Transpl Infect Dis; 2007 Mar; 9(1):60-1. PubMed ID: 17313476 [TBL] [Abstract][Full Text] [Related]
36. Current management of hepatitis C in New Zealand. Gane E N Z Med J; 2001 Mar; 114(1128):101-2. PubMed ID: 11346152 [No Abstract] [Full Text] [Related]
37. Peginterferon and ribavirin for hepatitis C. Evoli A; Servidei S N Engl J Med; 2007 Mar; 356(12):1269-70; author reply 1271. PubMed ID: 17380575 [No Abstract] [Full Text] [Related]
38. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients. Mira JA; López-Cortés LF; Merino D; Arizcorreta-Yarza A; Rivero A; Collado A; Ríos-Villegas MJ; González-Serrano M; Torres-Tortoso M; Macías J; Valera-Bestard B; Fernández-Fuertes E; Girón-González JA; Lozano F; Pineda JA; Antivir Ther; 2007; 12(8):1225-35. PubMed ID: 18240862 [TBL] [Abstract][Full Text] [Related]
39. [APRICOT Study evaluated. Surprisingly high virologic response in HIV-HCV coinfection]. MMW Fortschr Med; 2004 Apr; 146 Spec No 1():74-5. PubMed ID: 15373058 [No Abstract] [Full Text] [Related]
40. Is time to treat for HCV all the HIV/HCV co-infected hemophiliacs? Franchini M Hematology; 2006 Jun; 11(3):209-13. PubMed ID: 17325964 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]